Barclays
ACET icon

Barclays’s Adicet Bio ACET Stock Holding History

Barclays’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$170K Hold
25,000
– – ﹤0.01% 3782
2025
Q4 		$211K Buy
25,000
+6,250
+33% +$69.1K ﹤0.01% 4284
2025
Q3 		$243K Buy
18,750
+9,375
+100% +$110K ﹤0.01% 4207
2025
Q2 		$91.5K Buy
+9,375
New +$98.9K ﹤0.01% 4599
2025
Q1 		– Sell
-1
Closed -$13 – 5236
2024
Q4 		$13 Sell
1
-2
-67% -$38 ﹤0.01% 5223
2024
Q3 		$73 Sell
3
-22
-88% -$492 ﹤0.01% 5195
2024
Q2 		$479 Sell
25
-2,331
-99% -$62.5K ﹤0.01% 4709
2024
Q1 		$88.6K Sell
2,356
-256
-10% -$10.6K ﹤0.01% 4474
2023
Q4 		$79K Buy
2,612
+2,270
+664% +$49.5K ﹤0.01% 4690
2023
Q3 		$7.49K Sell
342
-14,043
-98% -$496K ﹤0.01% 4342
2023
Q2 		$559K Buy
14,385
+13,239
+1,155% +$1.17M ﹤0.01% 2681
2023
Q1 		$106K Sell
1,146
-5,020
-81% -$630K ﹤0.01% 4143
2022
Q4 		$882K Buy
6,166
+1,016
+20% +$254K ﹤0.01% 2907
2022
Q3 		$1.17M Buy
5,150
+5,061
+5,687% +$1.28M ﹤0.01% 2118
2022
Q2 		$21K Sell
89
-173
-66% -$38K ﹤0.01% 4369
2022
Q1 		$84K Buy
+262
New +$60.3K ﹤0.01% 3859
2020
Q3 		– Sell
-37
Closed -$9K – 5165
2020
Q2 		$9K Sell
37
-8
-18% -$1.57K ﹤0.01% 5331
2020
Q1 		$5K Sell
45
-94
-68% -$14K ﹤0.01% 5926
2019
Q4 		$23K Buy
139
+62
+81% +$31.4K ﹤0.01% 5945
2019
Q3 		$76K Sell
77
-11
-13% -$12.3K ﹤0.01% 5674
2019
Q2 		$101K Buy
88
+60
+214% +$54.4K ﹤0.01% 5685
2019
Q1 		$21K Buy
28
+22
+367% +$20K ﹤0.01% 6337
2018
Q4 		$6K Sell
6
-30
-83% -$39.5K ﹤0.01% 6360
2018
Q3 		$61K Sell
36
-8
-18% -$10.4K ﹤0.01% 5945
2018
Q2 		$45K Buy
44
+32
+267% +$34.5K ﹤0.01% 5694
2018
Q1 		$13K Buy
+12
New +$22K ﹤0.01% 6571

Other funds holding ACET

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Barclays's ACET Position: Q1 2026 in Review

Barclays held its Adicet Bio (ACET) position steady in Q1 2026 at 25,000 shares worth $170K. The position accounts for ﹤0.01% of the portfolio, ranked #3782.

Barclays first reported a position in ACET in Q1 2018 and has held it in 26 quarters since. The position peaked at $1.17M in Q3 2022. 49 funds tracked by Wall St. Rank hold ACET as of Q1 2026.

  • Barclays held 25,000 shares of Adicet Bio worth $170K as of Q1 2026.
  • Barclays left its Adicet Bio share count unchanged in Q1 2026.
  • Adicet Bio made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3782 holding.
  • Barclays first reported a position in Adicet Bio in Q1 2018 and has held it in 26 quarters since.
  • Barclays's Adicet Bio position peaked at $1.17M in Q3 2022.
  • 49 funds tracked by Wall St. Rank held Adicet Bio as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.